Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis

This publication has 50 references indexed in Scilit:

• Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
  Molecular Therapy, 2011
• Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin
  Molecular Therapy, 2011
• Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat
  Biochemistry, 2010
• Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
  Molecular Therapy, 2009
• Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs
  Nature Biotechnology, 2009
• Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease Patients
  Current Biology, 2009
• Sustained effects of nonallele‐specific Huntingtin silencing
  Annals of Neurology, 2009
• Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo
  Neurobiology of Disease, 2008
• Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice
  Molecular Therapy, 2005
• Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion
  Nature Genetics, 1997